Biogen Inc Pre-Recorded Presentation of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript

Edited Transcript of BIIB.OQ corporate analyst meeting

...Laura Nisenbaum Hello. My name is Laura Nisenbaum, I am the Head of the Diagnostic Pathways Group at Biogen and lead the biomarker strategy for aducanumab. It's my pleasure to present our work on cerebrospinal fluid biomarker concordance with amyloid PET from EMERGE and ENGAGE, our Phase III studies of aducanumab in patients with early Alzheimer's disease. Before moving into the results from my presentation, I provide here the disclosures from the authors of this work. I want to note that aducanumab is an investigational compound and is not yet approved. Finally, please note that this presentation may include forward-looking statements as detailed here. The data described in this presentation come from the EMERGE and ENGAGE Phase III aducanumab trials. These studies were identical in design, randomized, 18-month double-blind and placebo-controlled. Patients were in the early symptomatic stages of disease where symptoms are still limited. Patients were classified clinically as Mild Cognitive...

Transcript